BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Eletriptan (Relpax) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Eletriptan (Relpax)\, from ClinicalTrials
 .gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06677229-10371@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Eletriptan (Relpax): Phase 1/2 readout est. (NCT06677229)
DESCRIPTION:Eletriptan (Relpax)\, phase 1/2.\nStudy: Phase 1b/2a Clinical T
 rial to Determine the Safety\, Tolerability and Efficacy of TZ-161 in Spin
 al Cord Injury\nEstimated primary completion: December 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/eletriptan-relpax#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06677229
URL:https://assetmemo.bio/drug/eletriptan-relpax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
